Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 4
2012 2
2013 2
2014 2
2015 1
2016 1
2017 2
2018 1
2019 2
2020 4
2021 3
2022 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

26 results

Results by year

Filters applied: . Clear all
Page 1
The role of CDK6 in cancer.
Nebenfuehr S, Kollmann K, Sexl V. Nebenfuehr S, et al. Among authors: kollmann k. Int J Cancer. 2020 Dec 1;147(11):2988-2995. doi: 10.1002/ijc.33054. Epub 2020 May 30. Int J Cancer. 2020. PMID: 32406095 Free PMC article. Review.
Cyclin-dependent kinase inhibitors in malignant hematopoiesis.
Schirripa A, Sexl V, Kollmann K. Schirripa A, et al. Among authors: kollmann k. Front Oncol. 2022 Aug 11;12:916682. doi: 10.3389/fonc.2022.916682. eCollection 2022. Front Oncol. 2022. PMID: 36033505 Free PMC article. Review.
CDK4/6 and MAPK-Crosstalk as Opportunity for Cancer Treatment.
Scheiblecker L, Kollmann K, Sexl V. Scheiblecker L, et al. Among authors: kollmann k. Pharmaceuticals (Basel). 2020 Nov 24;13(12):418. doi: 10.3390/ph13120418. Pharmaceuticals (Basel). 2020. PMID: 33255177 Free PMC article. Review.
CDK6 Inhibition: A Novel Approach in AML Management.
Uras IZ, Sexl V, Kollmann K. Uras IZ, et al. Among authors: kollmann k. Int J Mol Sci. 2020 Apr 5;21(7):2528. doi: 10.3390/ijms21072528. Int J Mol Sci. 2020. PMID: 32260549 Free PMC article. Review.
CDK6 Antagonizes p53-Induced Responses during Tumorigenesis.
Bellutti F, Tigan AS, Nebenfuehr S, Dolezal M, Zojer M, Grausenburger R, Hartenberger S, Kollmann S, Doma E, Prchal-Murphy M, Uras IZ, Höllein A, Neuberg DS, Ebert BL, Ringler A, Mueller AC, Loizou JI, Hinds PW, Vogl C, Heller G, Kubicek S, Zuber J, Malumbres M, Farlik M, Villunger A, Kollmann K, Sexl V. Bellutti F, et al. Among authors: kollmann k. Cancer Discov. 2018 Jul;8(7):884-897. doi: 10.1158/2159-8290.CD-17-0912. Epub 2018 Jun 13. Cancer Discov. 2018. PMID: 29899063 Free PMC article.
Precision Medicine in Hematology 2021: Definitions, Tools, Perspectives, and Open Questions.
Valent P, Orfao A, Kubicek S, Staber P, Haferlach T, Deininger M, Kollmann K, Lion T, Virgolini I, Winter G, Hantschel O, Kenner L, Zuber J, Grebien F, Moriggl R, Hoermann G, Hermine O, Andreeff M, Bock C, Mughal T, Constantinescu SN, Kralovics R, Sexl V, Skoda R, Superti-Furga G, Jäger U. Valent P, et al. Among authors: kollmann k. Hemasphere. 2021 Feb 17;5(3):e536. doi: 10.1097/HS9.0000000000000536. eCollection 2021 Mar. Hemasphere. 2021. PMID: 33623882 Free PMC article. Review.
CDK6 and p16INK4A in lymphoid malignancies.
Kollmann K, Sexl V. Kollmann K, et al. Oncotarget. 2013 Nov;4(11):1858-9. doi: 10.18632/oncotarget.1541. Oncotarget. 2013. PMID: 24161991 Free PMC article. No abstract available.
The interplay of CDK4 and CDK6 in melanoma.
Kollmann K, Briand C, Bellutti F, Schicher N, Blunder S, Zojer M, Hoeller C. Kollmann K, et al. Oncotarget. 2019 Feb 15;10(14):1346-1359. doi: 10.18632/oncotarget.26515. eCollection 2019 Feb 15. Oncotarget. 2019. PMID: 30858922 Free PMC article.
CDK6 Degradation Is Counteracted by p16INK4A and p18INK4C in AML.
Schmalzbauer BS, Thondanpallil T, Heller G, Schirripa A, Sperl CM, Mayer IM, Knab VM, Nebenfuehr S, Zojer M, Mueller AC, Fontaine F, Klampfl T, Sexl V, Kollmann K. Schmalzbauer BS, et al. Among authors: kollmann k. Cancers (Basel). 2022 Mar 18;14(6):1554. doi: 10.3390/cancers14061554. Cancers (Basel). 2022. PMID: 35326705 Free PMC article.
26 results